MO

MEGHAN O'BRIEN

EDWARDS LIFESCIENCES, LLC · Irvine, CA · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
5 agencies contacted
Activity
filings by quarter
Works on

Background

Career
Irvine, CA
2024 - present

Specific issues

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Medicare/Medicaid · 2025 Q1
Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Health Issues · 2025 Q1
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Medicare/Medicaid · 2024 Q4
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Health Issues · 2024 Q4
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Medicare/Medicaid · 2024 Q3
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness Cybersecurity for Healthcare Industry AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Health Issues · 2024 Q3

Clients

2024-2025 · 4 filings
$██,███ / qtrUnlock

Filing history

2025 Q1
EDWARDS LIFESCIENCES LLC
Q1lda.gov →
2024 Q4
EDWARDS LIFESCIENCES LLC
Q4lda.gov →
2024 Q3
EDWARDS LIFESCIENCES LLC
Q3lda.gov →
2024 Q2
EDWARDS LIFESCIENCES LLC
Q2lda.gov →
Showing recent filings · full history on lda.gov